title: Management of Widespread Skin Thickening in Diffuse Systemic Sclerosis.
abstract: Skin thickening is one of the early organ manifestations of systemic sclerosis (SSc) and has a great impact on quality of life (QOL) as well as overall daily living in patients with SSc. The dynamic changes that occur as the disease progresses and as other organs become further involved present the treating physician with therapeutic challenges. Hence, when considering drug therapy for skin disease, the treating physician should consider a number of factors including disease duration, the rate of skin thickening, the extent of disease progression, organ involvements, and patient-related outcome measures, all of which impact the type of treatments considered. For early diffuse skin disease, we prefer the use of methotrexate (MTX). And when there is evidence of lung involvement or tendon friction rubs (given its association with ILD development), we tend to shift to the use of mycophenolate or cyclophosphamide because these agents have been shown efficacious for the specific indication of lung disease in SSc. We have managed joint disease, on the other hand when present, with MTX or other DMARDs, as well as the use of biologics when there is evidence of inflammatory polyarthritis or rheumatoid arthritis overlap. While the treatment of myositis in the setting of SSc can present a therapeutic dilemma, reluctantly, we may use steroids along with MTX, mycophenolate, intravenous immunoglobulin (IV-Ig), or rituximab. Ongoing clinical trials investigating the use of tocilizumab, abatacept, and other agents offer promising potential therapies. Great strides have been made in treating skin disease in SSc. And with recent trials focusing on early SSc disease, this will allow for a greater insight into the mechanisms underlying SSc especially as it relates to skin, and the expansion of future treatment options in this field.
authors.affiliation: David Geffen School of Medicine at UCLA, Division of Rheumatology, 1000 Veteran Ave, Rm 32-59, Los Angeles, CA, USA.
authors.forename: Suzanne
authors.initials: S
authors.lastname: Kafaja
authors.affiliation: David Geffen School of Medicine at UCLA, Division of Rheumatology, 1000 Veteran Ave, Rm 32-59, Los Angeles, CA, USA.
authors.forename: Philip
authors.initials: P
authors.lastname: Clements
keywords: Autologous stem cell transplantation; Cyclophosphamide; Diffuse cutaneous scleroderma; Intravenous immunoglobulin; Methotrexate; Mycophenolate; Rituximab; Systemic sclerosis; Tocilizumab